1432 related articles for article (PubMed ID: 26566750)
1. Cost-effectiveness of haemodialysis and peritoneal dialysis for patients with end-stage renal disease in Singapore.
Yang F; Lau T; Luo N
Nephrology (Carlton); 2016 Aug; 21(8):669-77. PubMed ID: 26566750
[TBL] [Abstract][Full Text] [Related]
2. Cost-Utility Analysis of Continuous Ambulatory Peritoneal Dialysis and Automated Peritoneal Dialysis for Thai Patients With End-Stage Renal Disease.
Thaweethamcharoen T; Sritippayawan S; Noparatayaporn P; Aiyasanon N
Value Health Reg Issues; 2020 May; 21():181-187. PubMed ID: 32044691
[TBL] [Abstract][Full Text] [Related]
3. Economic evaluation of palliative management versus peritoneal dialysis and hemodialysis for end-stage renal disease: evidence for coverage decisions in Thailand.
Teerawattananon Y; Mugford M; Tangcharoensathien V
Value Health; 2007; 10(1):61-72. PubMed ID: 17261117
[TBL] [Abstract][Full Text] [Related]
4. Cost utility analysis of end stage renal disease treatment in Ministry of Health dialysis centres, Malaysia: Hemodialysis versus continuous ambulatory peritoneal dialysis.
Surendra NK; Abdul Manaf MR; Hooi LS; Bavanandan S; Mohamad Nor FS; Firdaus Khan SS; Meng OL; Abdul Gafor AH
PLoS One; 2019; 14(10):e0218422. PubMed ID: 31644577
[TBL] [Abstract][Full Text] [Related]
5. Lifetime cost-effectiveness analysis of first-line dialysis modalities for patients with end-stage renal disease under peritoneal dialysis first policy.
Wong CKH; Chen J; Fung SKS; Mok M; Cheng YL; Kong I; Lo WK; Lui SL; Chan TM; Lam CLK
BMC Nephrol; 2020 Feb; 21(1):42. PubMed ID: 32019528
[TBL] [Abstract][Full Text] [Related]
6. Cost-Utility Analysis Using EQ-5D-5L Data: Does How the Utilities Are Derived Matter?
Yang F; Devlin N; Luo N
Value Health; 2019 Jan; 22(1):45-49. PubMed ID: 30661633
[TBL] [Abstract][Full Text] [Related]
7. Healthcare systems and end-stage renal disease (ESRD) therapies--an international review: costs and reimbursement/funding of ESRD therapies.
De Vecchi AF; Dratwa M; Wiedemann ME
Nephrol Dial Transplant; 1999; 14 Suppl 6():31-41. PubMed ID: 10528710
[TBL] [Abstract][Full Text] [Related]
8. Comparison of cost-utility between automated peritoneal dialysis and continuous ambulatory peritoneal dialysis.
Cortés-Sanabria L; Paredes-Ceseña CA; Herrera-Llamas RM; Cruz-Bueno Y; Soto-Molina H; Pazarín L; Cortés M; Martínez-Ramírez HR
Arch Med Res; 2013 Nov; 44(8):655-61. PubMed ID: 24211750
[TBL] [Abstract][Full Text] [Related]
9. Economic evaluation of centre haemodialysis and continuous ambulatory peritoneal dialysis in Ministry of Health hospitals, Malaysia.
Hooi LS; Lim TO; Goh A; Wong HS; Tan CC; Ahmad G; Morad Z
Nephrology (Carlton); 2005 Feb; 10(1):25-32. PubMed ID: 15705178
[TBL] [Abstract][Full Text] [Related]
10. Economic evaluation of three dialysis methods in patients with end-stage renal disease in China.
Hong Z; Zhuang Y; Lu J; Ye J; Sun H; Gao L; Xiong Y
Int Urol Nephrol; 2023 May; 55(5):1247-1254. PubMed ID: 36376531
[TBL] [Abstract][Full Text] [Related]
11. Economic costs of automated and continuous ambulatory peritoneal dialysis in Taiwan: a combined survey and retrospective cohort analysis.
Tang CH; Wu YT; Huang SY; Chen HH; Wu MJ; Hsu BG; Tsai JC; Chen TH; Sue YM
BMJ Open; 2017 Mar; 7(3):e015067. PubMed ID: 28325860
[TBL] [Abstract][Full Text] [Related]
12. Cost effectiveness evaluation of the Ministry of Health Malaysia dialysis programme.
Lim TO; Lim YN; Wong HS; Ahmad G; Singam TS; Morad Z; Suleiman AB; Rozina G; Ong LM; Hooi LS; Shaariah W; Tan CC; Loo CS
Med J Malaysia; 1999 Dec; 54(4):442-52. PubMed ID: 11072461
[TBL] [Abstract][Full Text] [Related]
13. Is CAPD a viable option among ADPKD with end stage renal disease population in India? Its outcomes and economics.
Kaul A; Dharshan R; Bhadhuaria D; Prasad N; Gupta A; Sharma RK
Saudi J Kidney Dis Transpl; 2015 Sep; 26(5):906-11. PubMed ID: 26354561
[TBL] [Abstract][Full Text] [Related]
14. Costs and added value of haemodialysis and peritoneal dialysis outsourcing agreements.
Lamas Barreiro JM; Alonso Suárez M; Saavedra Alonso JA; Gándara Martínez A
Nefrologia; 2011; 31(6):656-63. PubMed ID: 22130280
[TBL] [Abstract][Full Text] [Related]
15. Health economic evaluations: the special case of end-stage renal disease treatment.
Winkelmayer WC; Weinstein MC; Mittleman MA; Glynn RJ; Pliskin JS
Med Decis Making; 2002; 22(5):417-30. PubMed ID: 12365484
[TBL] [Abstract][Full Text] [Related]
16. [Cost-effectiveness of interventions for end-stage renal disease].
Arredondo A; Rangel R; de Icaza E
Rev Saude Publica; 1998 Dec; 32(6):556-65. PubMed ID: 10349148
[TBL] [Abstract][Full Text] [Related]
17. The economic cost of dialysis: a comparison between peritoneal dialysis and in-center hemodialysis in a Spanish unit.
Rodríguez-Carmona A; Perez Fontán M; Bouza P; García Falcón T; Valdés F
Adv Perit Dial; 1996; 12():93-6. PubMed ID: 8865880
[TBL] [Abstract][Full Text] [Related]
18. A cost effectiveness analysis of the treatment of end stage renal failure.
Croxson BE; Ashton T
N Z Med J; 1990 Apr; 103(888):171-4. PubMed ID: 2109846
[TBL] [Abstract][Full Text] [Related]
19. Superior survival of high transporters treated with automated versus continuous ambulatory peritoneal dialysis.
Johnson DW; Hawley CM; McDonald SP; Brown FG; Rosman JB; Wiggins KJ; Bannister KM; Badve SV
Nephrol Dial Transplant; 2010 Jun; 25(6):1973-9. PubMed ID: 20097847
[TBL] [Abstract][Full Text] [Related]
20. Hemodialysis versus peritoneal dialysis, which is cost-effective?
Atapour A; Eshaghian A; Taheri D; Dolatkhah S
Saudi J Kidney Dis Transpl; 2015 Sep; 26(5):962-5. PubMed ID: 26354569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
